Background and Objectives: Dry eye disease (DED) is a common and very symptomatic pathology that affects normal daily activity. The aim of the study was to evaluate the efficacy of plasma rich in growth factors (PRGF) added to one routine treatment protocol for DED (artificial tears substitutes, lid hygiene, and anti-inflammatory therapy).Materials and Methods: Patients were divided into two groups of treatment: standard treatment group (n= 43 eyes) and PRGF group (n= 59). Patients’ symptomatology (inferred from OSDI and SANDE questionnaires), ocular inflammation, tear stability, and ocular surface damage were analyzed at baseline and after 3 months of treatment.Results: OSDI test scores were significantly lower in both groups (p< 0.001). SANDE frequency test scores also improved statistically, with differences between groups (p= 0.0089 SANDE frequency andp< 0.0119 SANDE severity). There was a greater reduction in ocular redness (ocular inflammation) in the PRGF group (p< 0.0001) and fluorescein tear break-up time was significantly improved in the PRGF group (p= 0.0006). No significant changes were found in terms of ocular surface damage. No adverse events were obtained in either group.Conclusions: The addition of PRGF to the standard treatment of DED, according to the results obtained, proved to be safe and produced an improvement in ocular symptomatology and signs of inflammation, particularly in moderate and severe cases, when compared to standard treatment.